ANGLE (LSE:AGL) Short Interest

View and export this data going back to 2004. Start your Free Trial

What is ANGLE Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of ANGLE's Short Interest

For the Diagnostics & Research subindustry, ANGLE's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ANGLE's Short Interest Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ANGLE's Short Interest distribution charts can be found below:

* The bar in red indicates where ANGLE's Short Interest falls into.

Save Embed

;

Save Embed

;

ANGLE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ANGLE PLC (LSE:AGL) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

ANPCY:USA DWV:Germany

Address

10 Nugent Road, The Surrey Research Park, Surrey, Guildford, GBR, GU2 7AF

Website

https://www.angleplc.com

ANGLE PLC is active in the healthcare sector in the United Kingdom. The Company's principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy that is non-invasive cancer diagnostics. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which the majority of its revenue is generated from Europe.